Clinical usefulness of ramucirumab plus paclitaxel for unresectable and recurrent gastric cancer

INTRODUCTION: Recently in Japan, Ramucirumab (RAM) became the first anti-angiogenic agent to be approved for second-line treatment of gastric cancer. In the present study, we aimed to evaluate the efficacy and safety of RAM plus paclitaxel (PTX) in patients with unresectable and recurrent gastric ca...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Fukushima J Med Sci
Main Authors: Hayase, Suguru, Yamada, Leo, Ujiie, Daisuke, Nirei, Azuma, Tada, Takeshi, Hanayama, Hiroyuki, Monma, Tomoyuki, Saze, Zenichiro, Ohki, Shinji, Kono, Koji
Formato: Artigo
Idioma:Inglês
Publicado em: The Fukushima Society of Medical Science 2019
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6509409/
https://ncbi.nlm.nih.gov/pubmed/30996218
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5387/fms.2018-12
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados